Dec 30, 2025 03:43PM Jefferies on Inovio Pharmaceuticals (INO): 'Our near-term focus is on Type B outcome expected in ~50 days + ~30 days meeting minutes'

Dec 30, 2025 06:39AM H.C. Wainwright Reiterates Neutral Rating on Inovio Pharmaceuticals (INO)

Dec 29, 2025 08:05AM INOVIO BLA for rare respiratory disease treatment accepted by FDA

Dec 21, 2025 04:00AM Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026

Nov 14, 2025 08:11AM 'Inovio Pharmaceuticals (INO) Raises $28.75M to Fund Operations'; PT Raised at Piper Sandler

Nov 11, 2025 04:06AM Oppenheimer Upgrades Inovio Pharmaceuticals (INO) to Outperform

Nov 10, 2025 04:45PM Inovio Pharma (INO) Misses Q3 EPS by 87c

Nov 4, 2025 05:17AM Inovio Pharmaceuticals (INO) On Track for PDUFA Approval in <60 Days - Citizens

Nov 3, 2025 08:05AM INOVIO submits drug application for rare respiratory disease treatment

Aug 26, 2025 08:05AM INOVIO begins rolling submission for INO-3107 treatment approval

Aug 20, 2025 07:11AM Oppenheimer Reiterates Outperform Rating on Inovio Pharmaceuticals (INO)

Aug 13, 2025 05:45AM Inovio Pharmaceuticals (INO) PT Lowered to $1.80 at Jefferies

Aug 13, 2025 04:27AM Citizens JMP Reiterates Market Outperform Rating on Inovio Pharmaceuticals (INO)

Aug 12, 2025 04:28PM Inovio Pharma (INO) Misses Q2 EPS by 61c

Jul 9, 2025 04:40AM Piper Sandler Starts Inovio Pharmaceuticals (INO) at Overweight

Jul 3, 2025 07:30AM Inovio Pharma (INO) Prices $25M Offering at $1.75/sh

Jul 2, 2025 04:16PM Inovio Pharma (INO) Announces Proposed Share Offering

May 14, 2025 07:07AM Inovio Pharmaceuticals (INO) PT Lowered to $13 at Oppenheimer

May 14, 2025 04:14AM Citizens JMP Reiterates Market Outperform Rating on Inovio Pharmaceuticals (INO)

May 13, 2025 07:05PM Inovio Pharma (INO) Misses Q1 EPS by 51c

Mar 19, 2025 04:10AM Inovio Pharmaceuticals (INO) PT Lowered to $12 at Citizens JMP

Mar 18, 2025 04:09PM Inovio Pharma (INO) Misses Q4 EPS by 65c

Mar 14, 2025 04:43AM Citizens JMP Reiterates Market Outperform Rating on Inovio Pharmaceuticals (INO)

Feb 12, 2025 08:05AM Inovio Pharma (INO): Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Feb 3, 2025 04:43AM JMP Securities Biotechnology Overview

Dec 13, 2024 07:00AM Inovio Pharma (INO) Prices 10M Share Offering at $3/sh

Dec 12, 2024 04:01PM Inovio Pharma (INO) Announces Proposed Share Offering

Dec 3, 2024 08:06AM Inovio Pharma (INO): New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

Nov 18, 2024 07:42AM Inovio Pharmaceuticals (INO) PT Lowered to $15 at Oppenheimer

Nov 18, 2024 06:56AM Inovio Pharmaceuticals (INO) PT Lowered to $5 at H.C. Wainwright

Nov 15, 2024 06:33AM Inovio Pharmaceuticals (INO) PT Lowered to $6 at RBC Capital

Nov 14, 2024 05:38PM Inovio Pharma (INO) Misses Q3 EPS by 89c

Nov 13, 2024 08:04AM Inovio Pharma (INO) Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients

Aug 13, 2024 07:29AM Inovio Pharma (INO) enters Equity Distribution Agreement

Aug 9, 2024 06:26AM Inovio Pharmaceuticals (INO) PT Lowered to $8 at RBC Capital

Aug 8, 2024 04:29PM Inovio Pharma (INO) Misses Q2 EPS by 119c

Jul 25, 2024 04:22PM Inovio Pharma (INO) Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107

Jul 15, 2024 08:28AM H.C. Wainwright Reiterates Buy Rating on Inovio Pharmaceuticals (INO)

Jul 2, 2024 04:05PM Inovio Pharma (INO) Appoints Steven Egge as Chief Commercial Officer